A genetic variation in the adenosine A2A receptor gene (ADORA2A) contributes to individual sensitivity to caffeine

J V Rétey1, M Adam, R Khatami

  • 1Institute of Pharmacology and Toxicology, University of Zürich, and Department of Neurology, University Hospital, Zürich, Switzerland.

Insights

Caffeine affects sleep quality, especially in sensitive individuals, due to its action on adenosine A2A receptors. A specific gene variation (ADORA2A) influences how caffeine impacts sleep and brain activity.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Human Genetics

Background:

  • Caffeine is a widely consumed stimulant known to disrupt sleep quality.
  • Previous research in mice linked caffeine's sleep disruption to adenosine A2A receptor blockade.

Purpose of the Study:

  • To investigate the role of adenosine A2A receptors in caffeine's effects on human sleep.
  • To determine if genetic variations in the ADORA2A gene influence caffeine sensitivity and sleep quality.

Main Methods:

  • Human participants were assessed for habitual caffeine consumption, caffeine sensitivity, and sleep quality.
  • Genotyping of the adenosine A2A receptor gene (ADORA2A) c.1083T>C polymorphism was performed.
  • Electroencephalography (EEG) was used to measure brain electrical activity during sleep.

Main Results:

  • Habitual caffeine intake correlated with poorer sleep quality in self-reported caffeine-sensitive individuals.
  • Distinct ADORA2A c.1083T>C genotype distributions were observed between caffeine-sensitive and -insensitive adults.
  • The ADORA2A genotype influenced the similarity of caffeine-induced sleep EEG changes to those seen in insomnia.

Conclusions:

  • Adenosine A2A receptors play a significant role in regulating human sleep.
  • Common variations in the ADORA2A gene contribute to individual differences in subjective and objective responses to caffeine concerning sleep.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...